Pfs48/45 a member of a Plasmodium specific protein family displays conformation dependent epitopes and is an important target for malaria transmission blocking (TB) immunity. To design a recombinant Pfs48/45 based TB vaccine we analysed the conformational TB epitopes of Pfs48/45. The Pfs48/45 protein was found to consist of a Cterminal six-cysteine module recognized by anti-epitope I antibodies, a middle four-cysteine module recognized by anti-epitopes IIb and III, and a N-terminal module recognized by antiepitope V antibodies. Refolding assays identified that a fragment of 10 cysteines (10C) comprising the middle four-cysteine and the Cterminal six-cysteine modules possesses superior refolding capacity. The refolded and partially purified 10C conformer elicited antibodies in mice that targeted at least two of the TB epitopes (I and III). The induced antibodies could block the fertilization of P.falciparum gametes in-vivo in a concentration dependent manner. Our results provide important insight into the structural organization of the Pfs48/45 protein and experimental support for a Pfs48/45 based subunit vaccine.
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Malaria parasites are spread in the human population by Plasmodium-infected Anopheles mosquitoes. After a blood meal on infected humans, mosquitoes become infected by ingesting a sexual form of the malaria parasite called gametocytes. Subsequent sporogonic development in the mosquito can be prevented by the presence of anti-malaria, transmission blocking (TB) antibodies in the ingested blood meal (1) (2) (3) .
Pfs48/45 is a TB vaccine candidate that belongs to a family of malaria specific proteins that contain conserved motifs with four or sixcysteine residues (4). Pfs48/45 plays a key role in parasite fertilisation (5) and monoclonal antibodies (mAbs) against Pfs48/45 prevent fertilization (6) . Anti-Pfs48/45 antibodies are present in human sera from endemic areas and there is evidence that the presence of anti-Pfs48/45 antibodies in natural sera correlates with TB activity (7) . The induction of antibodies after natural infection as observed in the field creates the highly beneficial potential of vaccine boosting in the endemic setting. At least four different epitopes (I, IIb, III and V) on Pfs48/45 are targeted by monoclonal antibodies that block or reduce malaria transmission (8, 9) . Apart from epitope V, the TB epitopes are sensitive to reducing agents which indicates the importance of the disulfide bridges and hence the conformational dependence of these epitopes (8, 10) .
To design a Pfs48/45 based TB vaccine, we aimed to delineate and characterise the TB epitopes of Pfs48/45. Protease digestion of the native protein, expression in E.coli of truncations, cysteine mutations, and refolding assays were evaluated by immunological analysis of the TB epitopes. An N-terminally truncated protein with higher refolding efficiency was identified, partially purified and tested in mice immunization experiment. The elicited antibodies recognized the native Pfs48/45 protein, competed with the TB mAbs against epitopes I and III and displayed TB activity. Our study provides the first biochemical analysis of the Pfs48/45 protein and a blueprint for the design of Pfs48/45 based vaccines.
EXPERIMENTAL PROCEDURES
Native Pfs48/45 protein -Mature P. falciparum (NF54) gametocytes were produced as previously described (11) and extracted in 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% sodium deoxycholate (DOC), and 1 mM phenylmethylsulphonyl fluoride. Insoluble debris were removed by centrifugation at 13,000 g for 5 min at room temperature (RT). The supernatant contained native Pfs48/45 protein that was used in Western blot and ELISAs analyse.
Antibodies -Polyclonal rabbit antiserum K96 was used to detect recombinant Pfs48/45 (12) . To detect epitopes of Pfs48/45, various mAbs from mouse origin, 32F5 (epitope I) (6) or from rat origin, 85RF45.1 (epitope I), 85RF45.2b (epitope IIb), 85RF45.3 (epitope III) and 85RF45.5 (epitope V) (8) were used. Alkaline phosphatase (AP)-conjugated antisera were purchased from Sigma and horseradish peroxidase (HRP)-conjugated antisera from Nordic.
Partial protease digestion and purification of Pfs48/45 protease fragment -Partial protease treatment was conducted with trypsin (sequencing grade, Roche). For each digestion 5x10 5 gametocyte equivalents of the above described DOC extract were used. The proteins were digested at 25ºC for 1 h. The amount of protease varied from 0.01, 0.1 to 1 µg in a final reaction volume of 10 µl. The digestion was stopped by adding a protease inhibitor cocktail (Complete TM , Roche). For preparative immunopurification of protease fragments, 1x10 8 gametocyte equivalents were digested with 1 µg/ml trypsin for 2.5 h at 30ºC. A 28 kDa fragment was purified using mAb 32F5 against Pfs48/45 epitope I. This mAb 32F5 was cross-linked to Protein G-Sepharose 4B Fast Flow (Sigma) using dimethylpimelimidate (Sigma) (13) . The trypsin-treated extract was incubated overnight at 4ºC with the cross-linked beads, washed three times with 0.1% DOC in phosphate buffered saline (PBS) and 3 times with RIPA buffer (13) . Bound proteins were eluted twice with 500 µl 1% SDS in PBS at 70ºC (14). To identify the 28 kDa fragment, the eluted proteins were SDS-PAGE separated and stained with Coomassie brilliant blue R250 (Sigma). The 28 kDa doublet was sliced out from the gel and analyzed by Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (LC-MS/MS) as previously described (15) .
Constructs of truncated and mutated Pfs48/45 -
The coding sequence of Pfs48/45 (14) without the predicted signal peptide and GPI signal sequence (aa 27 to 427) was cloned into pGEX-2T (Amersham, Biosciences), resulting in a Nterminal GST-fusion. N-terminal truncated Pfs48/45 GST-fusions were generated using standard cloning techniques. Cysteines were mutated to serines by site-directed mutagenesis (QuikChange, Stratagene). For refolding experiments, Pfs48/45 fragments were cloned in the vector pET-15b (Novagen) resulting in Nterminally (His) 6 -tagged proteins. All constructs were verified by sequencing using BigDye (Applied Biosystems, ABI) and ABI PRISM 310 Genetic Analyzer.
Purification and refolding of E. coli expressed proteins -
The tagged proteins (GST or His) were expressed in the E.coli strain BL21 DE3 (Novagen) by induction for 3 hours at 37°C with 0.1 mM IPTG (GST-fusions) or 1 mM IPTG (Histagged) at an OD 600 nm of 0.6. The expressed proteins were analyzed in crude lysates or after affinity purification. Bacteria were lysed by ultrasonic homogenization in PBS, 1 mg/ml lysozyme, 0.1% triton X-100, 1 mM PMSF, 1x protease inhibitor cocktail (Complete TM , Roche). After centrifugation (10,000 x g for 15 min at 4°C), pellets containing the inclusion bodies were washed with 0.5% Triton X-100 in 10 mM Tris pH 8.0, 1 mM EDTA followed by 0.5% Triton X-100 in 10 mM Tris pH 8.0. The His-tagged proteins were purified using Ni-NTA beads (Qiagen) after solubilization of the inclusion bodies in 8 M urea, 50 mM Tris-HCl pH 8, 0.5 M NaCl, 1 mM β-mercaptoethanol. Folowing centrifugation (10 min 10.000 x g), the supernatant was loaded on a 10 ml disposable column (Bio-Rad) with 400 µl bed volume Ni-NTA beads. After 30 min of incubation at RT during slow vertical rotation, the beads were allowed to settle and the column was washed with 10 bed volumes of solubilization buffer, and 10 bed volumes 8 M urea, 50 mM Tris-HCl pH 8, 1 mM reduced glutathione. The tagged proteins were eluted 2-times with 0.75 ml of 10 mM EDTA in 8M urea, 0.5 M NaCl, 50 mM Tris-HCl, pH 8.0 and 1 mM glutathione. Eluted proteins at concentration of 0.25 µg/µl were 8-fold drop-wise diluted in renaturation buffer (PBS, 0.1% Triton X-100, 1 mM reduced glutathione and 1x protease inhibitor cocktail (Complete TM , Roche)) and refolded overnight at 4 °C.
Refolding on column and purification of 10C fragment -Inclusion bodies were prepared and solubilized as described above. The protein was then bound to a Ni-NTA resin and the column was washed with 8 M urea, 50 mM Tris-HCl pH 8, 0.5 M NaCl. The protein was refolded by subsequent buffer exchange to PBS that contained 0.1% Triton X-100 and the bound, refolded protein was eluted with 10 mM EDTA in the above described buffer. The eluted proteins were 50-fold concentrated on Vivaspin 20, 30000 MWCO filters (Vivascience). Insoluble aggregates were removed by centrifugation (30 min 13.000 x g) and protein was further purified over a Superdex 75 HR 10/30 column (Amersham Biosciences). Immunofluorescence assay (IFA) -An indirect IFA was performed with a mix of cultured asexual and sexual stage parasites (NF54 isolate of P.falciparum) air-dried on multispot slide as described previously (8, 11) . Briefly, parasites were incubated with a 1:100 dilution of the test sera in PBS, rinsed with PBS and incubated with FITC-conjugated goat anti-mouse IgG (Cappel, 55493). The slides were rinsed, washed, mounted under a cover slip and examined under ultraviolet illumination with a Leitz Ortholux fluorescence microscope (500 x magnification). For surface IFA (SIFA) analysis, gametocytes were allowed to undergo gametogenesis as described previously (8, 11) .
SDS-PAGE and immunoblot analysis -
Subsequently suspension of macrogametes/zygotes (100µl) was mixed with 100 µl of a 1:100 dilution of the sera in PBS and incubated for 20 minutes on ice. Parasites were washed with 1 ml PBS, collected by centrifugation for 3min at 3000 rpm (benchtop centrifuge) and incubated with 50 µl FITC-conjugated goat antimouse IgG (Cappel, 55493). After wash with PBS, the cells were examined as for the IFA.
Direct Enzyme Linked Immunosorbent Assay
(ELISA) -ELISA plates were coated overnight with gametocyte extract (250,000 parasites/well) in PBS. After blocking with 5% milk in PBS, sera (in the desired dilutions) were incubated for 2 hours. Bound antibodies were detected by HRPconjugated Goat anti-Mouse IgG and visualized using TMB substrate as previously described (8, 11) .
Pfs48/45 specific Enzyme Linked Immunosorbent
Assay (ELISA) -A two-side ELISA was performed as previously described (8, 11) . Samples were treated with 10 mM iodoacetamide just before the serial dilution to prevent refolding in the wells. The amount of the native Pfs48/45 protein in the gametocyte extract was pre-determined by western blot analysis under reducing conditions, using the polyclonal antiserum K96 (12) and the recombinant protein as a reference.
Competition-ELISA -The Pfs48/45 protein present in gametocyte extract was captured essentially as for the Pfs48/45 specific ELISA using mAb 85RF45.2b. Competition of HRPOlabeled 85RF45.1 or 85RF.45.3 with sera antibodies from 10C-immunized mice was performed by incubation of 30 µl HRPO-labeled mAb (2.5 ug/ml, diluted with PBS containing 0.1% Milk) and 30 µl mice serum (dilutions ranging from 1/20 to 1/2,560 diluted with PBS containing 0.1% milk) for 2 hours. Bound, labeled mAbs were measured as described above.
Standard membrane feeding assay (SMFA) -Antisera obtained from mice immunized with the 10C fragment were compared for their TB activities in SMFAs as previously described (16, 17) . Briefly, 30 µl of the mice sera were mixed with 60 µl of naïve human serum and 180 µl of invitro gametocyte culture of P. falciparum (NF54 line). This mixture was fed to Anopheles stephensi (Nijmegen strain) mosquitoes through a membrane feeding apparatus. Sera from mice immunized with PBS buffer alone served as controls. Bloodfed mosquitoes were kept at 26°C and 80% humidity for seven days. Surviving mosquitoes (>90%) were dissected and oocysts counted from extracted midguts. Twenty mosquitoes per batch were examined for the presence of oocysts. An SMFA experiment was considered valid when in three control batches of mosquitoes fed on naïve human serum and in-vitro gametocyte culture the percentage of infected mosquitoes was 90% or more.
RESULTS
Protease mapping of the Pfs48/45 -To elucidate the domain organization of Pfs48/45 protein trypsin digestion was used. Trypsin recognition sites that are buried inside the protein should be relatively inaccessible. The Pfs48/45 protein contains in total 51 Lys and Arg residues, all of which are potential trypsin cleavage sites. Figure 1 shows the result of a trypsin digestion on gametocyte extract, separated under non reducing conditions on SDS-PAGE and analyzed by immunoblot with anti-Pfs48/45 epitope I mAb. A doublet migrating at about 28 kDa reacted with TB epitope I (Fig. 1A) as well as with IIb and III mAbs, but not with epitope V mAb (data not shown). Immuno-purification of the 28 kDa doublet using epitope I mAb and subsequent LC-MS/MS analysis identified peptides between residues 164 and 404 with a corresponding molecular weight of 28 kDa. Thus, Pfs48/45 contains a C-terminal part of 28 kDa that is relatively resistant to trypsin cleavage and that displays conformational epitopes I, IIb and III. At higher trypsin concentrations, a minor 18 kDa fragment was generated with weak epitope I ( 
Expression of GST fused N-terminal Pfs48/45
truncations in E. coli -To determine more precisely which regions are critical for epitope formation, full-length Pfs48/45 without its Nterminal signal peptide (SP) sequence and its Cterminal signal for attachment of a glycosylphosphatidylinositol moiety (GPI) (aa 27-427; 16C fragment, Fig. 2A ) and truncations thereof were constructed and expressed as Nterminal GST fusions in E. coli. Total E. coli proteins were boiled in SDS sample buffer with 50 mM DTT, resolved by SDS-PAGE, and blotted onto nitrocellulose membranes. The observed reactivity with the mAbs after blotting is likely a result of refolding of the protein on the nitrocellulose membrane. Expression of full-length Pfs48/45 fused to GST (16C, Fig. 2B ) resulted in a protein of approximately 80 kDa that was recognized by the polyclonal, non-conformation dependent K96 sera (12) and by the mAbs recognizing epitope I, IIb, III and V (8) (Fig. 2B) . A second polypeptide with an apparent molecular weight of 30 kDa was detected that is generated by initiation of translation at an internal start codon at methionine 174 due to the presence of a ShineDelgano like motif. This polypeptide was recognized by the mAbs I, IIb, and III and was absent when using constructs shorter than 10C, it migrated at the same position as 10C without the GST moiety.
In line with the trypsin sensitivity assays, the 10C fragment could be detected by epitopes I, IIb, and III mAbs. Furthermore, epitopes IIb and III were present in the 10C but not in the 8C or shorter fragments. Epitope I was present in all the C-terminal truncations including the 6C fragment (Fig. 2B) . MAb against epitope V displayed much stronger reactivity with the 16C than the 12C construct and no reactivity could be detected against the 10C or shorter fragments. Thus, the region between cysteines 4 and 7 appeared to be essential for epitope V and the region N-terminally to cysteine 4 appear to contribute for epitope V formation.
Epitope mapping by cysteine mutations -To investigate which cysteines are important for the proper formation of the TB epitopes, each cysteine was mutated to serine in the full-length Pfs48/45 fused to GST (16C). These sixteen individual mutants were expressed in E. coli and screened for formation of conformational epitopes I, IIb, III, and V.
In line with the previously proposed structural organization of Pfs48/45 (4,18) mutations of any of the six cysteines in the putative C-terminal domain led to the specific loss of epitope I recognition (Fig. 3) . This finding corroborated and extended our N-terminal truncations analysis and led to the conclusion that the epitope I mAb recognizes a conformational epitope at the Cterminus of the Pfs48/45 that requires proper pairing of six cysteines.
Mutations of any of the four-cysteines in the putative middle domain affected the recognition of epitopes IIb and III, but did not affect I and V. Hence, the middle four-cysteine part of the protein appears to form an independent conformational unit, in agreement with the N-terminal deletions experiments and previously proposed structural organization of Pfs48/45 (4, 18) . None of the cysteine mutations affected epitope V (Fig. 3) , in line with the fact that this epitope is not sensitive to reducing agents (10).
Re-folding and purification of the recombinant proteins -In E. coli the Pfs48/45 protein as well as truncations fused to GST ended up in inclusion bodies. To allow purifications from inclusion bodies we constructed N-terminal (His) 6 -tagged 16C, 12C, 10C, and 6C proteins. Reduction of the purified proteins before loading on gel and subsequent refolding on the nitrocellulose membrane showed that the 10C, 12C and 16C, but not 6C fragments could be partially refolded with respect to epitope I (Fig. 4A and B) . The proteins were further analyzed for their refolding potential by dilution in re-naturation buffer. Two-side capture ELISA experiment using mAb III for capture and mAb I and IIb for detection was employed to detect TB epitopes generated upon refolding (Fig. 4C) . Gametocyte extracts with empirically determined concentrations of native Pfs48/45 protein were used as standards. Out of the tested recombinant products, the 10C displayed the highest refolding potential with respect to the formation of TB epitopes.
Next we performed series of refolding experiments to optimize our refolding conditions. Different conditions such as redox couples, temperature, incubation time, urea concentration, type and amount of detergents, refolding by dilution and on various types of columns with one step, gradient, or cyclic re-naturation were tested. Single step refolding on Ni-NTA column yielded the highest refolding efficiency (data not shown). The refolding yielded aggregates in addition to a number of distinct monomeric conformers (Fig.  5A) . Subsequent concentration by diafiltration and purification on a Superdex 75 column separated monomeric conformers from the aggregates (Fig.  5B) . Although several monomeric conformers were observed under non reduced SDS-PAGE (Fig. 5B) , only one band with an apparent molecular weight of 28 kDa reacted with the mAbs. Capture ELISA experiments (Fig. 5C ) extended the western blot results showing that a fraction of the refolded 10C material displayed proper TB epitopes. About 10-20% of the protein was correctly folded i.e. displayed TB epitopes as estimated from the ELISAs, western blots and the silver stained SDS-PAGE.
Immunogenicity of the recombinant 10C
preparation -The immunogenicity of the refolded and partially purified 10C protein preparation was assessed by immunization of BALB/c mice. Groups of mice immunized with 10 5 or 10 6 P. falciparum (NF54) gametocytes or buffer (PBS) and adjuvant alone served as controls. Mice immunized with the 10C, but not the controls, induced antibodies that detected two bands in gametocyte extracts with the expected mobility of 48 and 45 kDa on western blots (data not shown). The immune responses were furthermore assessed by gametocyte ELISAs against total gametocyte antigens (Fig. 6A) , and Pfs48/45-ELISA in which native Pfs48/45 is captured by a mAb (Fig. 6B) . When analysed in the gametocyte ELISA, the 10C fragment induced titres of 1/11,400 (SD=1/8,355), which was about four times lower as compared to mice immunized with 10 6 gametocytes 1/40,000 (SD=1/14,142), and in a range similar to that of mice immunized with 10 5 gametocytes 1/7,500 (SD=1/2,179) (Fig. 6A) . Pfs48/45 ELISA revealed antibodies specific for the Pfs48/45 protein with a mean OD for the five mice of 0.958 (SD=0.447) (Fig. 6B) .
The ability of the antiserum to recognize native gametocyte or macrogamete protein was further assessed by immuno fluorescence assay (IFA) against whole dried sexual stage parasites and surface immuno fluorescence assay (SIFA) using live intact macrogametes/zygotes. Four out of five mice sera (10C1; 10C2; 10C4; 10C5) showed good reactivity to the gametocytes and macrogametes/zygotes but not against asexual stages or Pfs48/45 knock out parasites. The reactivity of the 10C1 serum is shown in figure  6C . Sera from mice immunized with buffer and adjuvant did not show detectable signal (not shown).
Having established the presence of antibodies specific against the native Pfs48/45 in the 10C immunized mice we investigated if the antibodies target known TB epitopes (I and III). Figure 7 shows a competition of the mice sera against a constant amount of peroxidise conjugated rat anti epitope I and III mAbs. The same but not conjugated rat anti epitope I and III mAb were used as positive controls and for quantification. All five sera from the 10C immunization competed with the conjugated epitope I mAb, while the control sera of adjuvant immunized mice as well as the pre-immune (S0) sera did not (Fig.  7A) .
Estimations from the amount of competitions in the mice sera compared to the competition observed with the non conjugated rat mAb, revealed that 10C1 serum contained anti-epitope I antibodies at concentrations of about 20 µg/ml. Sera 10C2, 10C3 and 10C5 contained lower titers of anti epitope I antibodies of about 6 µg/ml. The lowest epitope I competitor 10C4 contained anti epitope I antibodies in the range of 1-2 µg/ml. Competition with a non-TB epitope III mAb was observed for two of the 10C immunized mice (Fig.  7B) .
For the 10C1 serum anti-epitope III antibodies was estimated to be about 100 µg/ml and for the 10C4 about 20 µg/ml.
Previous characterizations of the anti-epitope I mAb revealed that concentration of 12 µg/ml or more completely blocks transmission (8) . Hence, the concentrations of the anti epitope I antibodies in the 10C1 serum was in the range expected to yield TB effects. The sera 10C2, 10C3 and 10C5 were expected to yield transmission reducing effects.
Transmission blocking activity induced by the 10C fragment -Antisera obtained from mice immunized with the recombinant 10C fragment were analysed for their TB activities relative to the anti-epitope I competiton ELISA. As shown in figure 8 , the strongest anti-epitope I competitor (10C1) blocked almost completely the oocyst development inside the mosquito midgut by reducing the mean oocyst number from about 7 in the controls to 0.45. Sera with intermediate antiepitope I antibodies (10C2, 10C3 and 10C5) reduced the oocyst numbers by approximately 50%. As expected the concentration of antiepitope I antibodies correlated to the TB reactivity. While achieving consistent and high titres of TB antibodies will be required for future vaccine development the data presented here shows that TB antibodies against the native Pfs48/45 can be induced in mice using recombinant, refolded Pfs48/45 protein fragment.
DISCUSSION
Our study provides the first biochemical and immunological characterization of Pfs48/45 and demonstrates that an N-terminally truncated Pfs48/45 protein, coined 10C, possesses highest refolding capacity and elicits TB antibodies that can block the fertilization of the P. faciparum gametes in a concentration dependent manner.
A multi-module organization of the Pf48/45 protein emerged as a result of extensive analysis using conformational dependent antibodies against Pfs48/45. A C-terminal module containing a sixcysteine module was recognized by mAb against epitope I, a middle module containing a fourcysteine module was recognized by mAbs against epitopes IIb and III, and an N-terminal module also containing a six-cysteine motif was recognized by the epitope V mAb. The cysteines in the central and the C-terminal modules appear to be crucial for proper presentation of the TB epitopes I, IIb and III. Proper display of the TB blocking epitope V in the N-terminal module did not depend on cysteines nor was it sensitive to treatment with reducing agents (10) . Limited trypsin digestion and refolding experiments indicated that the middle four-cysteine and the Cterminal six-cysteine module are likely to interact to form one stable domain of 10 cysteines whereas the N-terminal module of Pfs48/45 appears to form a separate domain.
Similar related four-and six-cysteine modules are present in ten other unique to Plasmodium proteins (4, 18) . Taken together our study corroborates and extends previous in-silico predictions on the disulphide bond structures and domain organization of Pfs48/45 and related proteins (4, 18) . While most of the Pfs48/45 related family members are largely uncharacterized, some of them are obvious TB vaccine candidates. Pfs48/45, P36p (5, 19) and Pfs230 (20) are expressed on the surface of the parasite and have essential function in development. In addition Pfs230 and Pfs48/45 are direct targets for TB antibodies (11, 20, 21) . While recombinant expression of these proteins in a proper conformation is expected to be cumbersome, combinations of various four-and six-cysteine modules may yield successful production strategy. Cloning and expression of similar to 10C protein fragments (four-cysteine module adjacent to sixcysteine module) from Pfs230 or other related proteins is expected to reveal the feasibility of this approach.
Previous studies revealed that in particular epitope I has strong TB potential (8) . This property seems not related to the origin of mAb itself but specific for the epitope that it recognizes as all of the epitope I (mouse and rat) block transmission completely whereas epitope IIb and III have no effect on their own (8) . The C-terminal six-cysteine module turned out to be the minimal portion of Pfs48/45 that could display epitope I (Fig. 4) . It appeared, however, that that fragment was not stable upon storage and highly sensitive to reducing conditions (data not shown). Interestingly, we consistently observed that the Cterminal six-cysteine module readily displayed epitope I on immunoblot when expressed as a GST fusion (Fig. 2) but not with the hexa-histidine tag (Fig. 4) . Apparently the GST moiety has a stabilizing effect on the conformation of Pfs48/45 similar to the middle four-cysteine module itself. The 10C fragment was stable upon storage and more resistant to treatment with reducing agents than the C-terminal 6C fragment (data not shown). Superdex 75 enriched 10 C conformer can be stored for at least 8 weeks at 4˚ C without detectable loss of reactivity with TB mAbs.
The ability of the refolded and partially purified 10C fragment to induce TB antibodies in rodent models such as mice was subsequently demonstrated in immunization experiments. The protein is immunogenic as it induced antibodies that specifically recognized the native Pfs48/45 protein. Competition ELISAs revealed that Pfs48/45 antibodies directed against TB blocking epitope I are present in the sera of mice immunized with the 10C protein. The concentration of epitope I and III antibodies varied in the five mice, one 10C1 was in the required range to efficiently block transmission (20 µg/ml). The same sera contained anti epitope III antibodies at concentration of 100 µg/ml indicating that epitope III is immuno-dominant over epitope I, which is in accordance with the observation that sera from malaria exposed individuals contain predominantly non-TB anti-epitope III antibodies and relatively low levels of anti-epitope I antibodies (11) . Apparently the middle fourcysteine module, recognized by epitope III retains higher immunugenicity as compared to the sixcysteine module, recognized by epitope I. The last from the other hand is crucial for the protective efficacy.
The potency of malaria TB vaccines is, amongst others, dependent on the concentration of the induced antibodies and the quantity of the fertilization competent gametocytes (8, 22, 23) . Thus the required magnitude of antibody responses is expected to depend on the load of mature gametocytes. Field data indicate that low concentrations of 'sub-microscopic' (<5000 gametocytes/ml) gametocytemia constitutes a considerable proportion (75%) of the human infectious reservoir in e.g. Kenyan children (24) . Mosquito infections rates for these submicroscopic carriers are about 4.1%; for the other carriers with microscopic densities the infections rates are 8.3%. In our transmission blocking assays, mosquitoes were fed on in-vitro grown gametocyte cultures that contain 1.5 x 10 6 /ml mature gametocytes with infection rates of > 90% of the fed mosquitoes. Therefore, it is expected that under field conditions the 10C induced antibody responses may yield sufficient TB effects.
The variability in the amount of induced antibody titres in the five of the 10C immunized mice resulted in variability in outcome on the TB assay. For the future it will be necessary to achieve uniform, sustained, and high-titre anti epitope I antibody responses in all of the 10C immunized animals or human individuals. For Pfs25H, another malaria TB vaccine candidate, the chemical conjugation to the outer-membrane protein complex of Neisseria meningitidis serogroup B and adsorption to aluminum hydroxyphosphate induced high and persistent antibody levels that yielded the desired uniform TB activity (25) . This, or similar approaches as described in (26) or (27) will be useful in the future in Pfs48/45 based vaccine formulations as they are expected to yield higher and uniform titres of TB antibodies and guarantee the efficacy of the 10C vaccine.
In conclusion the induction of TB antibodies using recombinant Pfs48/45 subunit protein provided a proof-of-concept for a recombinant Pfs48/45 based TB vaccine. Future efforts will be directed towards achieving a more homogeneous and correctly folded 10C preparation as well as improving the immunizations schemes and vaccine formulations. His-tagged C-terminal Pfs48/45 fragments 6C, 10C, 12C and 16C were expressed in E. coli and purified by Ni-NTA beads. After boiling in sample buffer with 50mM DTT, proteins were separated on a SDS-PAGE and (A) stained using coomassie brilliant blue R-250, or (B) immunoblot using anti epitope I (C, D). His tagged 6C, 10C, 12C and 16C constructs analyzed by two side ELISAs using rat mAbs against epitope III for capture and HRPlabeled rat mAbs for detection. Gametocyte extract with known concentration of the Pfs48/45 protein was used as a positive control. The re-folded proteins were treated with 10 mM iodoacetamide before dilution to prevent refolding in the microtiter plate. 
